Status:
COMPLETED
Providing Financial Incentives to Improve Adherence to Referral Eye Care Visits
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
Centers for Disease Control and Prevention
Conditions:
Glaucoma
Diabetic Retinopathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Glaucoma is a blinding eye disease increasingly common in older adults, particularly in African Americans, and often diagnosed late in the disease course. It is essential to develop novel health care ...
Detailed Description
The number of primary open angle glaucoma (POAG) cases will increase by 250% by 2050, directly affecting over 7 million lives. These numbers are specifically for POAG and do not include the many who a...
Eligibility Criteria
Inclusion
- African American or Hispanic ≥40 years
- Non-Hispanic white ≥50 years
- Anyone ≥ 18 years with diabetes
- Anyone ≥ 18 years with a glaucoma associated diagnosis
- Anyone ≥ 18 years with a family history of glaucoma
- All enrollees must be able to speak and understand English
Exclusion
- None
Key Trial Info
Start Date :
November 18 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2024
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT04328207
Start Date
November 18 2020
End Date
July 1 2024
Last Update
August 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233